Efficacy of a fixed combination of Centaurii herba, Levistici radix and Rosmarini folium in urinary lithiasis

Ceban, Emil

doi:10.1055/s-0031-1286040

Cited by 15 publications

(18 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prevention and treatment of renal stones in adults (as additive therapy in five studies) 3 , 11 , 12 , 17 , 18 …”

Section: Methodsmentioning

confidence: 99%

Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia

Naber¹

2013

RRU

View full text Add to dashboard Cite

This review evaluates 17 clinical studies from 18 selected publications concerning the safety, tolerability, and additional effects of the phytotherapeutic drug, Canephron® N (CAN, containing the medicinal plants, Centaurium erythraea, Levisticum officinale, and Rosmarinus officinalis) as standard therapy in various clinical settings. Its role in the prophylaxis and treatment of urinary tract infections in adults and in children, therapy and prophylaxis in adult patients with renal stones, treatment and prevention of urinary tract infections and other gestational diseases in pregnancy, and also its safety and tolerability. The dosage was as recommended and over a varying duration. Overall, CAN was shown to be effective in the treatment and prophylaxis of UTI compared with standard therapy, both in adults and children, and there was a reduced number of relapses. Children undergoing surgical correction of vesicoureteral reflux benefited from a prophylactic course of CAN. Ten-day add on therapy increased the rate of spontaneous elimination of kidney stones compared with standard therapy alone and may also have had a positive effect on stone prevention. Pregnant women showed earlier relief of symptoms and normalization of pyuria on additional treatment with the herbal combination. Only one adverse effect was reported (skin rash) in the 3115 patients included in this review. No teratogenic, embryotoxic, or fetotoxic effects, or negative interference with the psychological development or health of children born of mothers treated with the drug were reported. Because some of the studies were not well designed, their statistical significance remains unclear.

show abstract

“…Prevention and treatment of renal stones in adults (as additive therapy in five studies) 3 , 11 , 12 , 17 , 18 …”

Section: Methodsmentioning

confidence: 99%

Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia

Naber¹

2013

RRU

View full text Add to dashboard Cite

show abstract

“…Standardized preparations like Canephron N containing centaury, lovage, and rosemary exhibit not only anti-oxidative and nephroprotective but also diuretic and anti-inflammatory effects. This unique combination of antiurolithiatic effects is very promising 32, 33 . However, this has to be validated by randomized studies.…”

Section: Understanding Urolithiasismentioning

confidence: 99%

Recent advances in understanding and managing urolithiasis

Strohmaier

2016

F1000Res

View full text Add to dashboard Cite

During the last few years, there has been relevant progress in both understanding and managing urolithiasis. Our knowledge of stone formation has changed; although the importance of urine biochemistry was questioned by several investigators years ago, the decisive role of cellular processes (induced by oxidative stress) and the renal papilla has only recently been generally accepted as the most important step in stone formation. For calcium oxalate urolithiasis, the formation of papillary calcifications plays a key role and is of prognostic relevance. Further research has to concentrate on these aspects of preventing urolithiasis. Stone prevention (metaphylaxis) is a major issue when considering the burden it places on healthcare systems. An effective metaphylaxis could lower the cost of stone therapy significantly. For uric acid urolithiasis, so far there is only preliminary information available showing that papillary plaques are not as important as they are in calcium oxalate urolithiasis. Concerning stone management, endourology has improved stone therapy significantly during the last few years. Morbidity decreased and success (stone-free) rates increased. Therefore, the indications for extracorporeal shockwave lithotripsy (ESWL) narrowed. ESWL, however, still has its place in stone therapy. There is not one single treatment modality that is equally effective for all situations. It is important to observe the differential indications for different stones depending on size, localization, and composition.

show abstract

“…Prophylactic administration of the HMP in children undergoing surgical correction of vesicoureteral reflux improved clinical outcomes [28]. Study results support its use as add-on in therapy after urinary stone lithotripsy and it may also have had a positive effect on prevention of urolithiasis [29,30]. Pregnant women showed earlier relief of symptoms and normalization of pyuria on additional treatment with the herbal combination [3].…”

Section: Introductionmentioning

confidence: 99%

A non-interventional, prospective, multicenter study for evaluation of the use of the herbal medicinal product Canephron® N in the pediatric outpatient population in Russia

et al. 2018

View full text Add to dashboard Cite

Background: A herbal medicinal product (HMP) with centaury, lovage, and rosemary as active ingredients (brand name: Canephron® N) has been widely used for treatment and prevention of urinary tract infections (UTIs) and other urinary system disorders. Non-clinical in vitro and in vivo data indicate its diuretic, spasmolytic, anti-inflammatory, antioxidative and analgesic effects. The purpose of this non-interventional, prospective, multicenter study was to collect data on the use of the HMP in the Russian pediatric outpatient population. Results: In total, 636 outpatients aged 1-17 years were enrolled. Of these, 634 received at least one dose of the HMP and were included in the safety set, which was used for analysis. 61 patients were 12-23 months, 227 were 2-5 years, 234 were 6-11 years and 112 were 12-17 years of age. The oral solution of the HMP was prescribed in 66.4%, and tablets (dragées) in 33.6% of the patients. For 48% of the patients the HMP was prescribed to treat an acute or chronic disease, 25% of the patients received it for prophylaxis, and 27% for both. More than half of the patients (53%) received the HMP as monotherapy. Main treatment indications were UTIs (34.1%) and pyelonephritis (30.0%). The proportion of UTIs was the highest within the youngest age group (51%), while the proportion of different cystitis forms increased in patients older than 2 years. Relevant proportions of different nephritis forms and urolithiasis were only observed in patients aged 12-17 years. Forms of cystitis were more frequent in female than in male patients (15% vs. 1%), while forms of nephritis, urolithiasis, and dysmetabolic nephropathy / crystalluria were more frequent in male patients. At the end of the observational period, 20% of the patients were reported as recovered from their disease, and 65% were reported to show improvements. For 91% of all patients with HMP monotherapy the investigators evaluated the effectiveness of the HMP as 'good' or 'very good'. Nearly all patients (99%) evaluated the tolerability as 'good'or 'very good'. Five adverse drug reactions were observed. Conclusions: The treatment of children aged 1-17 years with the HMP is safe and well tolerated. The study results support the use of the HMP for treatment and prophylaxis of urinary system diseases.

show abstract

Efficacy of a fixed combination of Centaurii herba, Levistici radix and Rosmarini folium in urinary lithiasis

Cited by 15 publications

References 2 publications

Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia

Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia

Recent advances in understanding and managing urolithiasis

A non-interventional, prospective, multicenter study for evaluation of the use of the herbal medicinal product Canephron® N in the pediatric outpatient population in Russia

Contact Info

Product

Resources

About

Efficacy of a fixed combination of Centaurii herba, Levistici radix and Rosmarini folium in urinary lithiasis

Cited by 15 publications

References 2 publications

Efficacy and safety of the phytotherapeutic drug Canephron&reg; N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia

Efficacy and safety of the phytotherapeutic drug Canephron&reg; N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia

Recent advances in understanding and managing urolithiasis

A non-interventional, prospective, multicenter study for evaluation of the use of the herbal medicinal product Canephron® N in the pediatric outpatient population in Russia

Contact Info

Product

Resources

About

Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia

Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia